Parathyroid gland enlargement may delay the response of secondary hyperparathyroidism to cinacalcet, Japanese researchers reported in Nephron Clinical Practice (2009; published online ahead of print).
In a study, clinically stable hemodialysis patients with secondary hyperparathyroidism resistant to conventional treatment received cinacalcet for six months.
In patients with glands smaller than 500 m3, all markers of bone metabolism and intact parathyroid hormone (PTH) were significantly decreased after three months of cinacalcet treatment, whereas no significant changes in these parameters, except for intact PTH, were observed after three months in subjects with glands 500 mm3 or larger. After six months, all markers of bone metabolism were significantly decreased in both groups.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.